肿瘤细胞治疗研究
英文原题：A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021.
A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过去曾致力于阐明靶向 CD38 抗体治疗 MM 的机制和有效性。
CD38是一种跨膜糖蛋白，在多发性骨髓瘤（MM）细胞上相对高表达；靶向CD38的抗体可通过多种机制杀伤MM细胞。免疫治疗可提高应答质量且毒性可接受，在MM治疗中潜力巨大。本研究通过文献计量学分析该领域相关文献，以识别其发展历程及结构关系。
从Web of Science核心合集（WoSCC）检索1985年至2021年6月21日发表的1,030篇相关文献。使用CiteSpace绘制作者、参考文献及国家的节点和连线图，提取高被引关键词并分析其时间趋势，识别共被引作者和文献，生成时区或时间线视图、突现词分析及双图叠加；使用VOSviewer识别期刊关联并构建合作网络；使用bibliometric.com追踪该领域的领先国家／地区。
全部文献总被引24,332次，平均每篇被引23.62次。美国发表论文最多，远超其他国家／地区。目前研究热点涉及“单克隆抗体”“难治性MM”“idecabtagene vicleucel”和“B细胞成熟抗原（BCMA）”等关键词。研究识别出10个重要聚类：“流式细胞术”“达雷妥尤单抗”“BCMA”“细胞系”“抗肿瘤活性”“基因”“非霍奇金淋巴瘤”“外周血”“生存”和“抗CD38”。既往研究关注靶向CD38抗体治疗MM的机制和疗效；未来热点将聚焦复发／难治性多发性骨髓瘤（RRMM）患者的新疗法。
过去的研究着重阐明靶向CD38抗体治疗MM的机制和疗效；未来研究热点将聚焦用于RRMM患者的抗BCMACAR-T 细胞免疫疗法。本文可帮助新进研究者了解该领域的发展历程和结构关系。
CD38 is a transmembrane glycoprotein that is relatively highly expressed on multiple myeloma (MM) cells, and CD38-targeting antibodies use pleiotropic mechanisms to kill MM cells. Immunotherapy, with an increased quality of response and acceptable toxicity, shows tremendous potential for treating MM. This research field study aimed to analyze all the relevant literature via bibliometrics to identify its course of development and structural relationships.
A total of 1,030 relevant articles were retrieved from the Web of Science Core Collection (WoSCC) from 1985 to June 21, 2021. CiteSpace was employed to map authors/references/countries with nodes and links, extract highly cited keywords, analyze the time trends of keywords, recognize cocited authors/references, set timezone or timeline views, analyze burstness and generate a dual map. VOSviewer was used to recognize connections among journals and construct collaboration networks. bibliometric.com was utilized to trace advanced countries/regions in the research field.
All of the articles were cited 24,332 times in total, with an average of 23.62 times. Most articles were published in the United States of America (USA), far outweighing other countries/regions. The current hotspots in this field are related to the following keywords: "monoclonal antibody", "refractory MM", "idecabtagene vicleucel", and "B cell maturation antigen (BCMA)". Ten significant clusters, namely, "flow cytometry", "daratumumab", "BCMA", "cell line", "antitumor activity", "gene", "non-Hodgkin's lymphoma", "peripheral blood", "survival" and "anti-CD38", were extracted. The mechanism and effectiveness of CD38-targeting antibodies in treating MM have been studied. Future research hotspots will focus on new therapies for relapsed and refractory multiple myeloma (RRMM) patients.
In the past, efforts were applied to elucidate the mechanism and effectiveness of CD38-targeting antibodies in treating MM. Future research hotspots will focus on anti-BCMA chimeric antigen receptor T cell (CAR-T) immunotherapy for patients with RRMM. According to this article, new researchers can discover its course of development and structural relationships in this field.
MEMBER ACCOUNT
登录成功会直接打开下一页。
